Association of eGFR and Albuminuria with Venous Thromboembolism.
Journal
Clinical journal of the American Society of Nephrology : CJASN
ISSN: 1555-905X
Titre abrégé: Clin J Am Soc Nephrol
Pays: United States
ID NLM: 101271570
Informations de publication
Date de publication:
01 Mar 2024
01 Mar 2024
Historique:
received:
26
05
2023
accepted:
10
11
2023
pmc-release:
01
03
2025
medline:
11
3
2024
pubmed:
17
11
2023
entrez:
16
11
2023
Statut:
ppublish
Résumé
CKD has been implicated as a risk factor of venous thromboembolism, but the evidence is limited to relatively healthy populations. The objective of this study was to discern whether parameters of kidney function and damage are associated with the occurrence of venous thromboembolism after hospitalization. We conducted a retrospective study including 23,899 and 11,552 adult individuals hospitalized within Geisinger Health System and New York University (NYU) Langone Health from 2004 to 2019 and 2012 to 2022, respectively. A Poisson model was used to evaluate adjusted incidence rates of venous thromboembolism according to eGFR and albuminuria categories in each cohort. Cox proportional hazards models were used to analyze associations of eGFR and urinary albumin-to-creatinine ratio (UACR) with venous thromboembolism, and hazard ratios (HRs) were meta-analyzed across cohorts. Both lower eGFR and higher UACR were associated with higher risks of venous thromboembolism. In the Geisinger cohort, the incidence of venous thromboembolism after hospital discharge ranged from 10.7 (95% confidence interval [CI], 9.2 to 12.6) events per 1000 person-years in individuals in G1A1 (eGFR >90 ml/min per 1.73 m 2 and UACR <30 mg/g) to 27.7 (95% CI, 20.6 to 37.2) events per 1000 person-years in individuals with G4-5A3 (eGFR <30 ml/min per 1.73 m 2 and UACR >300 mg/g). A similar pattern was observed in the NYU cohort. Meta-analyses of the two cohorts showed that every 10 ml/min per 1.73 m 2 reduction in eGFR below 60 ml/min per 1.73 m 2 was associated with a 6% higher risk of venous thromboembolism (HR 1.06 [95% CI, 1.02 to 1.11], P = 0.01), and each two-fold higher UACR was associated with a 5% higher risk of venous thromboembolism (HR 1.05 [95% CI, 1.03 to 1.07], P < 0.001). Both eGFR and UACR were independently associated with higher risk of venous thromboembolism after hospitalization. The incidence rate was higher with greater severity of CKD. This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_12_14_CJN0000000000000352.mp3.
Sections du résumé
BACKGROUND
BACKGROUND
CKD has been implicated as a risk factor of venous thromboembolism, but the evidence is limited to relatively healthy populations. The objective of this study was to discern whether parameters of kidney function and damage are associated with the occurrence of venous thromboembolism after hospitalization.
METHODS
METHODS
We conducted a retrospective study including 23,899 and 11,552 adult individuals hospitalized within Geisinger Health System and New York University (NYU) Langone Health from 2004 to 2019 and 2012 to 2022, respectively. A Poisson model was used to evaluate adjusted incidence rates of venous thromboembolism according to eGFR and albuminuria categories in each cohort. Cox proportional hazards models were used to analyze associations of eGFR and urinary albumin-to-creatinine ratio (UACR) with venous thromboembolism, and hazard ratios (HRs) were meta-analyzed across cohorts.
RESULTS
RESULTS
Both lower eGFR and higher UACR were associated with higher risks of venous thromboembolism. In the Geisinger cohort, the incidence of venous thromboembolism after hospital discharge ranged from 10.7 (95% confidence interval [CI], 9.2 to 12.6) events per 1000 person-years in individuals in G1A1 (eGFR >90 ml/min per 1.73 m 2 and UACR <30 mg/g) to 27.7 (95% CI, 20.6 to 37.2) events per 1000 person-years in individuals with G4-5A3 (eGFR <30 ml/min per 1.73 m 2 and UACR >300 mg/g). A similar pattern was observed in the NYU cohort. Meta-analyses of the two cohorts showed that every 10 ml/min per 1.73 m 2 reduction in eGFR below 60 ml/min per 1.73 m 2 was associated with a 6% higher risk of venous thromboembolism (HR 1.06 [95% CI, 1.02 to 1.11], P = 0.01), and each two-fold higher UACR was associated with a 5% higher risk of venous thromboembolism (HR 1.05 [95% CI, 1.03 to 1.07], P < 0.001).
CONCLUSIONS
CONCLUSIONS
Both eGFR and UACR were independently associated with higher risk of venous thromboembolism after hospitalization. The incidence rate was higher with greater severity of CKD.
PODCAST
UNASSIGNED
This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_12_14_CJN0000000000000352.mp3.
Identifiants
pubmed: 37971889
doi: 10.2215/CJN.0000000000000352
pii: 01277230-202403000-00008
pmc: PMC10937012
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
301-308Subventions
Organisme : NHLBI NIH HHS
ID : K24 HL155861
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK115534
Pays : United States
Organisme : NIH HHS
ID : K24HL155861
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01DK115534
Pays : United States
Informations de copyright
Copyright © 2023 by the American Society of Nephrology.
Références
Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis. 2006;21(1):23–29. doi: 10.1007/s11239-006-5572-y
doi: 10.1007/s11239-006-5572-y
Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3–14. doi: 10.1007/s11239-015-1311-6
doi: 10.1007/s11239-015-1311-6
Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5(4):692–699. doi: 10.1111/j.1538-7836.2007.02450.x
doi: 10.1111/j.1538-7836.2007.02450.x
Dartevelle P, Fadel E, Mussot S, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2004;23(4):637–648. doi: 10.1183/09031936.04.00079704
doi: 10.1183/09031936.04.00079704
Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350(22):2257–2264. doi: 10.1056/NEJMoa032274
doi: 10.1056/NEJMoa032274
Kahn SR, Kearon C, Julian JA, et al. Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis. J Thromb Haemost. 2005;3(4):718–723. doi: 10.1111/j.1538-7836.2005.01216.x
doi: 10.1111/j.1538-7836.2005.01216.x
Roumen-Klappe EM, den Heijer M, Janssen MCH, van der Vleuten C, Thien T, Wollersheim H. The post-thrombotic syndrome: incidence and prognostic value of non-invasive venous examinations in a six-year follow-up study. Thromb Haemost. 2005;94(4):825–830. doi: 10.1160/TH05-03-0146
doi: 10.1160/TH05-03-0146
Baldwin MJ, Moore HM, Rudarakanchana N, Gohel M, Davies AH. Post-thrombotic syndrome: a clinical review. J Thromb Haemost. 2013;11(5):795–805. doi: 10.1111/jth.12180
doi: 10.1111/jth.12180
Guérin L, Couturaud F, Parent F, et al. Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb Haemost. 2014;112(3):598–605. doi: 10.1160/TH13-07-0538
doi: 10.1160/TH13-07-0538
Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur Respir J. 2017;49(2):1601792. doi: 10.1183/13993003.01792-2016
doi: 10.1183/13993003.01792-2016
Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23 suppl 1):I9–I16. doi: 10.1161/01.CIR.0000078469.07362.E6
doi: 10.1161/01.CIR.0000078469.07362.E6
Llach F. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. Kidney Int. 1985;28(3):429–439. doi: 10.1038/ki.1985.149
doi: 10.1038/ki.1985.149
Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ. Thrombosis and hemostasis in renal disease. Kidney Int. 1994;46(2):287–296. doi: 10.1038/ki.1994.274
doi: 10.1038/ki.1994.274
Crew RJ, Radhakrishnan J, Appel G. Complications of the nephrotic syndrome and their treatment. Clin Nephrol. 2004;62(4):245–259. doi: 10.5414/cnp62245
doi: 10.5414/cnp62245
Singhal R, Brimble KS. Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res. 2006;118(3):397–407. doi: 10.1016/j.thromres.2005.03.030
doi: 10.1016/j.thromres.2005.03.030
Mahmoodi BK, Gansevoort RT, Veeger NJ, et al. Microalbuminuria and risk of venous thromboembolism. JAMA. 2009;301(17):1790–1797. doi: 10.1001/jama.2009.565
doi: 10.1001/jama.2009.565
Wattanakit K, Cushman M, Stehman-Breen C, Heckbert SR, Folsom AR. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol. 2008;19(1):135–140. doi: 10.1681/ASN.2007030308
doi: 10.1681/ASN.2007030308
Ocak G, Verduijn M, Vossen CY, et al. Chronic kidney disease stages 1-3 increase the risk of venous thrombosis. J Thromb Haemost. 2010;8(11):2428–2435. doi: 10.1111/j.1538-7836.2010.04048.x
doi: 10.1111/j.1538-7836.2010.04048.x
Mahmoodi BK, Gansevoort RT, Næss IA, et al. Association of mild to moderate chronic kidney disease with venous thromboembolism: pooled analysis of five prospective general population cohorts. Circulation. 2012;126(16):1964–1971. doi: 10.1161/CIRCULATIONAHA.112.113944
doi: 10.1161/CIRCULATIONAHA.112.113944
Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737–1749. doi: 10.1056/NEJMoa2102953
doi: 10.1056/NEJMoa2102953
Sumida K, Nadkarni GN, Grams ME, et al. Conversion of urine protein-creatinine ratio or urine dipstick protein to urine albumin-creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant-based meta-analysis. Ann Intern Med. 2020;173(6):426–435. doi: 10.7326/M20-0529
doi: 10.7326/M20-0529
Clausen P, Feldt-Rasmussen B, Jensen G, Jensen JS. Endothelial haemostatic factors are associated with progression of urinary albumin excretion in clinically healthy subjects: a 4-year prospective study. Clin Sci. 1999;97(1):37–43. doi: 10.1042/cs0970037
doi: 10.1042/cs0970037
Dubin R, Cushman M, Folsom AR, et al. Kidney function and multiple hemostatic markers: cross sectional associations in the multi-ethnic study of atherosclerosis. BMC Nephrol. 2011;12:3. doi: 10.1186/1471-2369-12-3
doi: 10.1186/1471-2369-12-3
Keller C, Katz R, Cushman M, Fried LF, Shlipak M. Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol. 2008;9:9. doi: 10.1186/1471-2369-9-9
doi: 10.1186/1471-2369-9-9
Yang K, Du C, Wang X, et al. Indoxyl sulfate induces platelet hyperactivity and contributes to chronic kidney disease-associated thrombosis in mice. Blood. 2017;129(19):2667–2679. doi: 10.1182/blood-2016-10-744060
doi: 10.1182/blood-2016-10-744060
Chang MC, Wang TM, Yeung SY, et al. Antiplatelet effect by p-cresol, a uremic and environmental toxicant, is related to inhibition of reactive oxygen species, ERK/p38 signaling and thromboxane A2 production. Atherosclerosis. 2011;219(2):559–565. doi: 10.1016/j.atherosclerosis.2011.09.031
doi: 10.1016/j.atherosclerosis.2011.09.031
Karbowska M, Kaminski TW, Marcinczyk N, et al. The uremic toxin indoxyl sulfate accelerates thrombotic response after vascular injury in animal models. Toxins (Basel). 2017;9(7):229. doi: 10.3390/toxins9070229
doi: 10.3390/toxins9070229
Bazilinski N, Shaykh M, Dunea G, et al. Inhibition of platelet function by uremic middle molecules. Nephron. 1985;40(4):423–428. doi: 10.1159/000183512
doi: 10.1159/000183512
Davis JW, McField JR, Phillips PE, Graham BA. Guanidinosuccinic acid on human platelet. Effects of exogenous urea, creatinine, and aggregation in vitro. Blood. 1972;39(3):388–397. doi: 10.1182/blood.v39.3.388.388
doi: 10.1182/blood.v39.3.388.388
Kim S, Martin C, White J, et al. Validation of an algorithm to identify venous thromboembolism in health insurance claims data among patients with rheumatoid arthritis. Clin Epidemiol. 2023;15:671–682. doi: 10.2147/CLEP.S402360
doi: 10.2147/CLEP.S402360
Fang MC, Fan D, Sung SH, et al. Validity of using inpatient and outpatient administrative codes to identify acute venous thromboembolism: the CVRN VTE study. Med Care. 2017;55(12):e137–e143. doi: 10.1097/MLR.0000000000000524
doi: 10.1097/MLR.0000000000000524